Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The SURGE(Supporting UnderRepresented minorities in Genomics-based cancer trial Enrollment) intervention is a patient navigation intervention that will support patients in their decision to consent to PROFILE OncoPanel (DFCI protocol 17-000). Consent to PROFILE allows patients to receive genomic testing as part of cancer clinical trial eligibility.
Eligible Conditions
- Lymphoma
- Thoracic Cancers
- Gastrointestinal Cancers
Treatment Effectiveness
Effectiveness Progress
Other trials for Lymphoma
Study Objectives
2 Primary · 10 Secondary · Reporting Duration: From the end of accrual, up to 3 years following study initiation
Year 3
Change in readiness and awareness of clinical trials
Clinical trial awareness/readiness and PROFILE genomic testing correlates
Consent rates to PROFILE
Consent to PROFILE genomic testing and precision clinical trial enrollment
Consent to PROFILE genomic testing but insufficient tissues for sequencing
Consent to PROFILE genomic testing but no archival tissue for sequencing
Consent to PROFILE genomic testing with GI TARGET review and precision clinical trial enrollment
Consent to Rapid Heme Panel and precision clinical trial enrollment
Initial readiness and awareness of clinical trials
No consent to PROFILE genomic testing after video
PROFILE genomic testing completion rates
Questionnaire response rate
Trial Safety
Safety Progress
Other trials for Lymphoma
Trial Design
2 Treatment Groups
Standard of Care (SOC)
1 of 2
SURGE
1 of 2
Experimental Treatment
100 Total Participants · 2 Treatment Groups
Primary Treatment: SURGE · No Placebo Group · N/A
Standard of Care (SOC)
Behavioral
Experimental Group · 1 Intervention: Standard of Care · Intervention Types: BehavioralSURGE
Behavioral
Experimental Group · 1 Intervention: SURGE · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard of Care
2017
Completed Phase 4
~9880
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from the end of accrual, up to 3 years following study initiation
Closest Location: Dana Farber Cancer Institute · Boston, MA
2004First Recorded Clinical Trial
101 TrialsResearching Lymphoma
539 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:The DFCI satellite is located at St
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments